Rapid development of Acinetobacter baumannii resistance to tigecycline. - Test2 - elhamkhani - TriplyDB

Rapid development of Acinetobacter baumannii resistance to tigecycline.

Rapid development of Acinetobacter baumannii resistance to tigecycline.

http://www.wikidata.org/entity/Q34581377

about

Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections First emergence of acrAB and oqxAB mediated tigecycline resistance in clinical isolates of Klebsiella pneumoniae pre-dating the use of tigecycline in a Chinese hospital The growing burden of antimicrobial resistance.Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.Ertapenem-induced reduction in valproate levels: case report and review of the literature Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.Drug treatment for multidrug-resistant Acinetobacter baumannii infections.Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States.Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine Interleukin-1 receptor antagonist gene polymorphism in patients with multidrug-resistant Acinetobacter baumannii-associated pneumonia.Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy Acinetobacter baumannii: An Emerging and Important Pathogen.Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California Epidemiology of antimicrobial resistance in bloodstream infections.The current state of multidrug-resistant gram-negative bacilli in North America.Therapeutic options for Acinetobacter baumannii infections.Acinetobacter baumannii: an emerging multidrug-resistant threat.Tigecycline for the treatment of Acinetobacter infections: a case series.In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.Tigecycline: a critical update.Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections Establishing the role of tigecycline in an era of antimicrobial resistance.Emergence and management of drug-resistant enterococcal infections.Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from a Chinese university hospital.Tigecycline treatment for urinary tract infections: case report and literature review.Therapeutic options for Acinetobacter baumannii infections: an update.Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management.Tetracycline Antibiotics and Resistance.Acinetobacter baumannii infection in solid organ transplant recipients.In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy.In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii.Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections.Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective.Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii.Tigecycline for treatment of nosocomial-acquired pneumonia possibly caused by multi-drug resistant strains of Stenotrophomonas maltophilia.

P2860

Q26823357-E400078A-545E-4D23-8B47-A4D4F514321F Q26991886-803A3624-BC24-43EA-8F5B-045665AF5564 Q28542706-5D6E9227-BD74-4A5C-87BE-D188EA147548 Q30371239-98149689-3A74-4390-8E99-C1D045BC85B1 Q33776590-CC809426-7E99-4197-BBDF-797017F0C75B Q34100039-8A147397-D657-436A-93B7-5A50E570734F Q34109281-D5261C69-6A8D-44DB-92E6-10256E21CC13 Q34601684-EB6D9FFA-E92A-42B3-8535-A456AC908436 Q34803735-D2151F49-E456-4B40-9F11-7C8F5B119F31 Q35530666-C978FBE9-A6C1-4663-BAF9-32608C7AE89B Q35598359-759CFD32-059A-4015-85A7-FC768B6C58FB Q35919549-FB5C6A7E-74E1-4E33-AEF3-C387287A76DB Q36048290-1DBDD318-96E2-4C14-B358-178C7CBCF4EF Q36509591-61857BE3-67DD-4964-9D2D-D8A58924C3CF Q36664292-16B7DDF1-AEEB-4582-8CC2-373F7F4C9C57 Q36845404-4E00E78B-BEEC-4A58-A298-C81F93F2405B Q36913239-DCA4FFC8-A665-4B48-BE87-AD982CACDB40 Q37069191-492C95CC-68B7-4B0F-8B68-91826465B633 Q37099006-A288A5A9-11C9-4B7B-B0B8-7689438C2191 Q37202840-E906FD4D-F7C6-483E-96CB-7F5EC4C2502E Q37211560-32D01A14-78CA-4510-9EB1-A6FCB34B1F31 Q37220041-9F07D5D3-4734-4DA5-B219-185439AE514A Q37233932-0277E9A8-7B71-4777-A262-58F2887206B4 Q37247772-E76B76FC-E921-4713-925B-A67190D6E30C Q37291328-C9F7A978-F308-40B8-900B-E710A048067A Q37291346-B8A2A72B-CBFF-44E4-B348-6313BDF35FB0 Q37544374-55D60969-F1EB-43E4-B594-4103F144128F Q37899640-09B551DF-78CF-4BB1-8107-2A8C63C26259 Q38049332-CFBA018F-2719-4C04-A8C6-DB6EEF4ED501 Q38097120-5F400475-2EBB-4A68-BF0A-3123F10BB4C9 Q38779243-6BB5E6CB-138C-4D9C-A665-C8A869E3FFDA Q41549501-966F9AD4-F614-4C1F-8FE5-095F9037714C Q41904163-FED21D00-CE0C-4F3C-B1A2-703D771417F8 Q42125230-334BB33F-0251-4968-A2A7-CBFD824179EC Q42612214-603DEE9A-1B10-4B89-81DA-09C646094AC2 Q42695527-0D12D3DF-5298-4F67-A528-981BED380D25 Q43077123-7D7AC3B3-F3B7-486E-B9EC-D2C2BFB76AA4 Q43237048-8F3F3B42-13B8-417D-B28B-162025CEEE2D Q43243027-416446DD-FB2F-4B71-8DFE-71B54B4A69E9 Q46172016-977802D9-A2D7-46F0-BDB2-0D0DF48F27F0

P2860

Rapid development of Acinetobacter baumannii resistance to tigecycline.

http://www.wikidata.org/entity/Q34581377

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Rapid development of Acinetobacter baumannii resistance to tigecycline.

@ast

Rapid development of Acinetobacter baumannii resistance to tigecycline.

@en

Rapid development of Acinetobacter baumannii resistance to tigecycline.

@nl

type

label

Rapid development of Acinetobacter baumannii resistance to tigecycline.

@ast

Rapid development of Acinetobacter baumannii resistance to tigecycline.

@en

Rapid development of Acinetobacter baumannii resistance to tigecycline.

@nl

prefLabel

Rapid development of Acinetobacter baumannii resistance to tigecycline.

@ast

Rapid development of Acinetobacter baumannii resistance to tigecycline.

@en

Rapid development of Acinetobacter baumannii resistance to tigecycline.

@nl

P1433

Q34581377-D79F11CF-F61D-4F99-8F11-2E121C92985C

P1476

Q34581377-CECECA78-7C88-48A6-A7DC-76BF616353B0

P2093

Q34581377-57E515BD-2132-415F-B2E5-9534D6E7A495

Q34581377-997DCC38-722B-466F-90C1-930BC322694C

Q34581377-C970A6F1-AE48-419D-BB36-21B89C8AC9EC

Q34581377-E77FE6B2-FEF5-4666-B560-47FE241B7B74

P2860

Q34581377-11BF8E6A-3541-4602-89B6-C0BADBB25A4B

Q34581377-2F97922D-BD57-474A-A7B8-68F49DC6C730

Q34581377-6AD5402C-2BAE-42DB-97E8-0CA32F7A9B08

Q34581377-723121CD-7D93-4BDD-A6E7-463CD710D6B1

Q34581377-75074D7A-24AF-4F7B-B790-BF635F59E8EB

Q34581377-832F16F8-3CAD-4C6C-A94D-A80041AE9CF5

Q34581377-A16535A8-7D24-4551-96B8-52D01523E24F

Q34581377-CAF86AEA-A40C-4A74-8BE2-2F4AEEDA4197

Q34581377-CCF62D3A-6C2D-4ADF-BB13-64C0BF49C7BE

Q34581377-D52291E4-C3F7-4D79-94C7-AF7A9EE8E97B

P304

Q34581377-96CCE7AB-F56B-4095-B82A-B78CED3E299B

P31

Q34581377-4C7E7CA5-A208-4DA6-A74A-2ECB924C6018

P356

Q34581377-B9A08F5D-858E-412D-9989-689BCF541122

P407

Q34581377-B525BC19-9CA1-4334-B463-9267BE88C74A

P433

Q34581377-020F301F-BC05-4C59-AEA1-21F4FD22EB5E

P478

Q34581377-98EB27A1-4771-4883-8905-70D2823F74F8

P50

Q34581377-7FCE19BD-D8A5-453E-9F7C-ADA1E3E1B14D

P577

Q34581377-A578785E-03CE-4302-BC2B-C6DF0A14D6F7

P698

Q34581377-C57314D4-7E4E-499F-A763-0CBA318A2DF4

P921

Q34581377-9F1D3D1C-B579-49F5-ADAA-13F56B613796

P356

P1433

Pharmacotherapy

P1476

Rapid development of Acinetobacter baumannii resistance to tigecycline.

@en

P2093

Christine A Aldeza

http://www.w3.org/2001/XMLSchema#string

Gail E Reid

http://www.w3.org/2001/XMLSchema#string

Shellee A Grim

http://www.w3.org/2001/XMLSchema#string

William M Janda

http://www.w3.org/2001/XMLSchema#string

P2860

The glycylcyclines: a comparative review with the tetracyclines

Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa

Tigecycline: what is it, and where should it be used?

Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.

Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.

Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem.

Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines.

AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii.

A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline.

In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan.

P304

1198-1201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.27.8.1198

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17655518

http://www.w3.org/2001/XMLSchema#string

P921

Acinetobacter baumannii